QIAGEN and Incyte have forged a new global precision medicine collaboration to develop a multimodal next-generation sequencing (NGS) companion diagnostic panel specifically designed for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. This advanced diagnostic tool will focus on detecting clinically relevant gene alterations, with an initial and significant emphasis on identifying mutant CALR (calreticulin), which is the second most common genetic driver of MPNs. The development aims to support Incyte's extensive portfolio of investigational therapies, including their monoclonal antibody INCA033989, which selectively targets mutCALR in myelofibrosis (MF) and essential thrombocythemia (ET). QIAGEN will validate this panel on the Illumina NextSeq 550Dx platform for use with whole blood samples and will manage regulatory submissions and market access activities across the United States, European Union, and Asia-Pacific regions. This partnership is crucial for advancing precision medicine in MPNs, as identifying these key genomic aberrations is vital for guiding clinicians in making targeted treatment decisions that can lead to significantly better patient outcomes by selectively targeting malignant cells.